GHRS
GH Research PLC
NASDAQ · Healthcare · Biotechnology · IE
$28.23
+1.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 268.0K | 335.0K | — | — | — |
| Gross Profit | (268.0K) | (335.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 46.7M | 38.7M | 35.0M | 29.8M | 20.5M |
| SG&A Expense | 24.5M | 21.6M | 15.0M | 11.1M | 10.1M |
| General & Admin Expense | 7.1M | — | 15.0M | 11.1M | 10.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 294.0K | 280.0K | 14.0K |
| Total Operating Expenses | 71.2M | 60.3M | 50.3M | 41.2M | 30.6M |
| Cost and Expenses | 71.4M | 60.7M | 50.3M | 41.2M | 30.6M |
| Operating Income (EBIT) | (71.4M) | (60.7M) | (50.3M) | (41.2M) | (30.6M) |
| Non-Operating | |||||
| Interest Income | 2.1M | 2.6M | 2.6M | 1.9M | 858.0K |
| Interest Expense | 201.0K | 463.0K | 717.0K | 723.0K | — |
| Net Interest Income | 1.9M | 2.2M | 1.9M | 1.2M | 858.0K |
| Other Non-Op Income/Expense | 9.2M | 12.4M | 11.4M | 5.6M | 8.1M |
| Non-Operating Income (excl Interest) | (9.4M) | (12.9M) | (11.4M) | (5.7M) | (8.1M) |
| EBT (Pre-Tax Income) | (62.3M) | (48.3M) | (39.0M) | (35.6M) | (22.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (62.3M) | (48.3M) | (39.0M) | (35.6M) | (22.5M) |
| Earnings from Cont. Ops | (62.3M) | (48.3M) | (39.0M) | (35.6M) | (22.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (62.3M) | (48.3M) | (39.0M) | (35.6M) | (22.5M) |
| Per Share | |||||
| Basic EPS | ($1.00) | ($0.79) | ($0.75) | ($0.68) | ($0.14) |
| Diluted EPS | ($1.00) | ($0.79) | ($0.75) | ($0.68) | ($0.14) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.5M | 61.0M | 52.0M | 52.0M | 52.0M |
| Diluted Shares Outstanding | 66.5M | 61.0M | 52.0M | 52.0M | 52.0M |
| Profitability Metrics | |||||
| EBITDA | (61.7M) | (47.5M) | (38.6M) | (35.2M) | (22.4M) |
| D&A | 359.0K | 335.0K | 315.0K | 315.0K | 47.0K |
| EBIT | (62.1M) | (47.8M) | (38.9M) | (35.5M) | (22.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026